Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | CPA1 | P15085 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014195 | 1.00 | CTSC (0.36) | CTSCALDH1A1CACNA2D1MMEACE | |
| SCHEMBL4005337 | 1.00 | CTSC (0.36) | CTSCALDH1A1CACNA2D1MMEACE | |
| SCHEMBL4014292 | 0.87 | CTSC (0.35) | CTSCALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL4009847 | 0.87 | CTSC (0.35) | CTSCALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL4014983 | 0.87 | CTSC (0.35) | CTSCALDH1A1CACNA2D1CACNB3CACNA1C | |
| SCHEMBL4015178 | 0.84 | PLA2G2C (0.36) | CTSC | |
| SCHEMBL4009104 | 0.84 | PLA2G2C (0.36) | CTSC | |
| SCHEMBL4014957 | 0.84 | PLA2G2C (0.36) | CTSC | |
| SCHEMBL4014948 | 0.83 | GABRR1 (0.33) | ALDH1A1ENPEPGABRR1 | |
| SCHEMBL4005588 | 0.82 | ENPEP (0.34) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | CTSC 1232/4885ALDH1A1 1058/4885CACNA2D1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.